We next investigated whether IMP3 expression could be a prognostic marker for high-grade gliomas, and we found that immunoreactive IMP3-HGG showed a shorter overall and disease-free survival than IMP3-negative cases (P = 0.0002 and P = 0.006, resp.; Figure 2(a)). This evidence concerns the gene IMP3 and glioma.